#option agreement

1 story

#business #cancer treatment #car therapy #cd22 nanobody #me therapeutics #money #national research council of canada

ME Therapeutics Extends CD22 Nanobody Option Agreement
ME Therapeutics extends option to license Canadian nanobody for cancer therapy until February 2027.
Financialpost · 1m